Malignant Melanoma of Unknown Primary Origin Presenting as Cardiac Metastasis

Eun Young Lee, MD, Jin-Oh Choi, MD, Ha Na Park, MD, Eun-Jung Park, MD, Gil Sun Lee, MD, Jun Young Park, MD, Jung-Sun Kim, MD, and Eun Seok Jeon, MD
Department of Internal Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea

Malignant melanoma has a very high propensity to metastasize to the heart. However, melanoma may sometimes present as a metastatic lesion in the absence of a primary lesion, which are called melanomas of unknown primary origin. We report a case in which a patient presented with a metastatic malignant melanoma in the right atrium with pericardial effusion and without a primary origin. (Korean Circ J 2012;42:278-280)

KEY WORDS: Melanoma; Neoplasma, unknown primary; Unknown primary; Heart neoplasms.

Introduction

Malignant melanomas are tumors with the highest rates of cardiac metastasis. However, cardiac metastasis is diagnosed in less than 1% of patients with malignant melanoma because less than 10% of these patients present with cardiac symptoms.1-3 Identification of cardiac metastasis from melanoma usually means that the patient is suffering systemic metastasis. Unlike typical cardiac metastasized patients, we report a first case of a patient with a metastatic malignant melanoma in the heart without an identifiable primary source or additional metastasis in Korea.

Case

A 59-year-old woman was admitted for cough and pleuritic chest pain with no history of malignancy or heart disease. Her initial blood pressure was 110/70 mm Hg, pulse rate 70 beats/min, respiratory rate 20/min, and body temperature was 36.1°C. Jugular veins were not distended. No hepatomegaly or audible cardiac murmurs were present. Laboratory studies, including a complete blood count, liver, and chemical profiles were in normal ranges. Electrocardiography revealed a normal sinus rhythm. Chest radiography showed cardiomegaly without abnormal lesions in bilateral lung fields. Chest computed tomography showed a large amount of pericardial effusion and a mass in the right atrium (RA) (Fig. 1). Trans-thoracic echocardiography showed a large mass measuring 42 × 31 mm in the RA, which did not obstruct tricuspid valve flow. Her ejection fraction was normal (Fig. 2). Pericardiocentesis was performed. Effusion analysis showed a red blood cell count of 1.9 × 10^5/mm^3 and a white blood cell count of 3300/mm^3 (lymphocytes, 55%; neutrophils, 14%). No malignant cells in the pericardial fluid were noted. Cardiac MRI also revealed a large mass surrounding ascending aorta spread into transverse sinus and around pulmonary trunk (Fig. 3).

Instead of tumor resection, considering the risk of open heart surgery and poor prognosis of extensive cardiac metastasis, pericardial window operation and epicardial mass biopsy were performed to relieve symptoms and confirm the pathological diagnosis. Pathological analysis including immunohistochemistry revealed the final diagnosis to be malignant melanoma (Fig. 4). The primary cutaneous melanoma could not be identified despite careful dermatological examination. The patient had no history of halo nevus or mole removal. Positron emission tomography revealed no other distant organ metastasis except for heart and mediastinal lymph nodes.
Discussion

Malignant melanoma has aggressive biological behavior and the greatest tendency for metastasis to the heart. Although autopsy studies reported an incidence of 50% to 71%, cardiac metastases is diagnosed in less than 1% of patients with malignant melanoma because less than 10% of these patients present with cardiac symptoms. Such metastases most frequently occur after multifocal hematological dissemination and may develop anywhere in the heart. Melanotic metastases can invade the wall of any of the 4 cardiac chambers, and the RA is involved most frequently.

The clinical signs and symptoms of cardiac metastasis are unclear and non-specific, although when present, the clinical signs and symptoms include fatigue, weakness, pericardial effusion, congestive heart failure, cardiac arrhythmia, superior vena cava syndrome, right ventricular outflow and inflow obstruction, and transient ischemic attack. However, patients with malignant melanoma who have cardiac metastases may present symptoms only caused by tumors in other organ systems. Although cardiac involvement occurs during the course of the disease, it is rare that the initial manifestation is cardiac metastasis.

A tumor’s anatomic location and extent of invasion determine the feasibility of surgical intervention, which should optimally be performed during the early stages of the disease. A complete resection of an intracardiac melanoma prevents potential morbidities that are associated with progressive intracardiac growth, such as superior vena cava syndrome, right ventricular outflow and inflow obstruction, dysrhythmia, cardiac tamponade, and heart failure. Even when total resection is not possible, conservative surgery can relieve symptoms and prevent imminent cardiac failure. Conservative surgery improves the quality of a patient’s life, as in our patient’s case.

Although more than 90% of melanomas have a cutaneous origin, melanomas may sometimes present metastatically in the absence of a primary lesion, termed melanomas of unknown primary origin. Most authors estimate that 2-6% of patients are diagnosed with metastatic melanoma of unknown primary site. In particular, such a metastatic melanoma in the heart such as in this patient without a known primary cutaneous origin is a rare presentation and chiefly an anecdotal finding of metastatic melanoma. Several reported cases can be found in the literature about cardiac involvement with cutaneous primary malignant melanoma and multiple metastasis in Korea, as well as worldwide. As far as we know, malignant cardiac melanoma without a primary origin has not yet been reported in Korea.

The survival of patients with unknown primary melanoma was demonstrated to be similar to that of patients with known primary tu-
280  Malignant Melanoma of Unknown Primary Origin Presenting as Cardiac Metastasis

Fig. 4. Pathology and immunohistochemistry of the pericardial biopsy. A: cytoplasmic melanin-pigmented cells and prominent nucleoli were found (×200). B: in immunohistochemistry, antibodies to HMB45 were positive (×200).

mors when corresponding stages were compared. Those patients with metastases to any other visceral sites are described to have a 1 year survival rate of 41% and a median survival of approximately 6 months. Accordingly, we expected that the outcome of this patient might be very unfavorable. Although total resection was not possible because of extensive cardiac metastasis, a pericardial window operation could resolve her symptoms.

After surgery, chemotherapy was planned, including cisplatin, dacarbazine, carmustine, and tamoxifen. However, the patient refused further chemotherapy after completion of two sessions. The patient has survived for 14 months after diagnosis. She is attending our hospital’s outpatient oncology department.

As only few reports about cardiac metastasis of malignant melanoma without cutaneous origin have been published, we are uncertain if conservative surgery is associated with prolonged survival and if the role of surgery for survival is worth further investigation.

References

1. Ozyuncu N, Sahin M, Altin T, Kariaoguz R, Guldal M, Akyurek O. Cardiac metastasis of malignant melanoma: a rare cause of complete atrioventricular block. Europe 2006;8:545-8.
2. MacGee W. Metastatic and invasive tumors involving the heart in a geriatric population: a necropsy study. Virchows Arch A Pathol Anat Histopathol 1991;419:183-9.
3. Savoia P, Fiero MT, Zaccagna A, Bernengo MG. Metastatic melanoma of the heart. J Surg Oncol 2000;75:203-7.
4. Malouf JF, Thompson RC, Maples WJ, Wolfe JT. Diagnosis of right atrial metastatic melanoma by transesophageal echocardiographic-guided transvenous biopsy. Mayo Clin Proc 1996;71:1167-70.
5. Qu G, Kaur JS, Seward JB. Metastatic melanoma presenting as cardiac mass and hemobilia. Am J Med Sci 2003;325:157-9.
6. Basarici I, Demir I, Yilmaz H, Altekin RE. Obstructive metastatic malignant melanoma of the heart: imminent pulmonary arterial occlusion caused by right ventricular metastasis with unknown origin of the primary tumor. Heart Lung 2006;35:351-4.
7. Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade: the American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664-78.
8. Lee KS. Resection of cardiac metastasis of malignant melanoma. Korean Circ J 2000;30:1170-4.
9. Kim OG, Hong JM, Lee SJ, Hong JS. Cardiac metastasis of malignant melanoma: a case report. Korean J Thorac Cardiovasc Surg 1999;32:840-3.
10. Baab GH, McBride CM. Malignant melanoma: the patient with an unknown site of primary origin. Arch Surg 1975;110:896-900.
11. Schlagenhauff B, Strobel W, Ellwanger U, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer 1997;80:60-5.
12. Katz KA, Jonasch E, Hodi FS, et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 2005;15:77-82.
13. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group Trials. J Clin Oncol 2000;18:3782-93.
14. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.